Olatuton (Octreotide Acetate)

Olatuton is a somatostatin analog that modulates hormone‑secretion pathways in several endocrine conditions.

• Acromegaly: reduces excess growth‑hormone production and helps control disease activity.
• Neuroendocrine tumours: controls tumour‑related hormone secretion and alleviates flushing and diarrhoea.
• Carcinoid syndrome: diminishes flushing, wheezing and diarrhoea associated with serotonin excess.
• VIPoma: lowers vasoactive intestinal peptide levels and reduces severe watery diarrhoea.
• Post‑operative pancreatic fistula prevention: decreases pancreatic secretions after major abdominal surgery.

• Octreotide acetate binds with high affinity to somatostatin receptors (mainly sst2 and sst5) on endocrine cells, inhibiting cyclic AMP formation and calcium influx. This receptor activation suppresses the release of several hormones—including growth hormone, insulin, glucagon, gastrin and vasoactive intestinal peptide—thereby reducing hormone‑driven clinical effects.

Adverse reactions to Olatuton are generally related to its hormonal inhibition and injection‑site tolerability.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Abdominal pain: cramp‑like discomfort.
• Diarrhoea or constipation: altered bowel habits.
• Injection‑site reactions: redness, swelling or bruising.
• Headache: transient head discomfort.
• Hyperglycaemia: elevated blood‑sugar levels.

Serious or Rare Side Effects

• Gallbladder disease: sludge or stones leading to biliary colic.
• Pancreatitis: inflammation of the pancreas.
• Severe hypoglycaemia: dangerously low blood‑sugar, especially in diabetic patients.
• Cardiac arrhythmias: irregular heart rhythm.
• Anaphylaxis: acute allergic reaction requiring immediate medical care.

When using Olatuton, clinicians should assess patient‑specific factors and monitor for known risks.

• Cardiovascular assessment: evaluate for existing heart disease before initiating therapy.
• Glycaemic monitoring: check blood‑glucose levels in diabetic or pre‑diabetic patients.
• Gallbladder evaluation: consider ultrasound screening for patients with a history of gallstones.
• Pregnancy and lactation: avoid unless the potential benefit outweighs risk.
• Renal or hepatic impairment: adjust monitoring frequency as organ function may affect drug clearance.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreotide may interact with several medicines that influence hormone levels or gastrointestinal motility.

Major Interactions (Avoid)

• Insulin or oral hypoglycaics: may potentiate hypoglycaemia.
• Cytochrome P450 3A4 inducers: can reduce octreotide exposure.

Moderate Interactions (Monitor Closely)

• Somatostatin analogues other than Olatuton: additive hormonal suppression.
• Proton‑pump inhibitors: may alter gastric pH and affect absorption of concomitant oral agents.
• Antiplatelet or anticoagulant drugs: increased risk of injection‑site bleeding.